Skip to main content

Table 1 Demographic, Genetic and Clinical Findings at baseline in Patients with early AMD

From: Functional effect of Saffron supplementation and risk genotypes in early age-related macular degeneration: a preliminary report

Pt.#, gender, age

CFH

ARMS2

Visual acuity

Follow-up duration

Fundus*

fERG§(n. of responses at B,V3, V6, V9, V12)

1, F, 52

HT

WT

0.8

6

Soft confluent drusen; central subfield

5(B), 5(V3), 5(V6)

2, M, 63

HT

WT

0.8

12

Soft confluent drusen and hypopigm.; central and middle subfield

4(B), 5(V3), 5(V6), 4(V9), 5(V12)

3, M, 70

HT

WT

0.7

12

Soft drusen; central subfield

4(B), 4(V3), 4(V6), 5(V9), 5(V12)

4, M, 73

HT

WT

0.7

12

Soft drusen; central and middle subfield

1(B), 5(V3), 6(V6), 6(V9), 6(V12)

5, M, 70

HO

WT

0.7

12

Soft confluent drusen; central subfield

5(B), 5(V3), 5(V6), 5(V9), 5(V12)

6, M, 73

HT

HT

1.0

12

Soft drusen; central subfield

4(B), 5(V3), 5(V6), 6(V9), 6(V12)

7, F, 65

HT

WT

0.9

6

Soft drusen; central subfield

4(B), 5(V3), 6(V6)

8, M, 55

HT

HO

1.0

12

Soft drusen and hyperpigm.; central subfield

5(B), 5(V3), 6(V6), 6(V9), 6(V12)

9, M, 79

HT

WT

0.5

12

Soft drusen and hyperpigm.; middle subfield

1(B), 1(V3), 4(V6), 6(V9), 6(V12)

10, F, 77

WT

WT

0.8

12

Soft drusen; middle subfield

4(B), 5(V3), 5(V6), 5(V9), 5(V12)

11, M,75

WT

HT

0.7

12

Soft drusen; middle subfield

4(B), 5(V3), 5(V6), 6(V9), 6(V12)

12, F, 70

HT

HT

0.7

12

Soft drusen and hyperpigm.; middle subfield

2(B), 2(V3), 1(V6), 3(V9), 3(V12)

13, F, 81

HT

WT

0.5

6

Soft drusen; middle subfield

4(B), 4(V3), 4(V6)

14, F, 54

HO

HT

0.6

12

Soft confluent drusen; middle subfield

6(B), 6(V3), 6(V6), 5(V9), 6(V12)

15, F, 64

HT

HO

1.0

12

Soft drusen and hypopigm.; middle subfield

2(B), 6(V3), 6(V6), 5(V9), 6(V12)

16, M,58

HT

WT

1.0

6

Soft drusen; middle subfield

1(B), 5(V3), 5(V6)

17, M,73

HT

HT

1.0

12

Soft drusen and hyperpigm.; middle subfield

4(B), 4(V3), 5(V6), 5(V9), 5(V12)

18, M,70

HT

WT

1.0

12

Soft drusen and hyperpigm.; central subfield

4(B), 5(V3), 5(V6), 4(V9), 4(V12)

19, F, 71

HO

WT

0.6

12

Soft confluent drusen and hypopigm.; central subfield

6(B), 6(V3), 5(V6), 5(V9), 6(V12)

20, M,61

HO

HO

0.5

12

Soft confluent drusen and hypopigm.; middle subfield

2(B), 6(V3), 5(V6), 6(V9), 6(V12)

21, F, 62

WT

WT

0.6

12

Soft drusen; middle subfield

6(B), 6(V3), 6(V6), 6(V9), 6(V12)

22, F, 71

HO

WT

1.0

12

Soft drusen; central and middle subfield

4(B), 5(V3), 5(V6), 6(V9), 5(V12)

23, M,68

HT

HO

0.8

12

Soft confluent drusen; central and middle subfield

2(B), 4(V3), 4(V6), 6(V9), 6(V12)

24, M,71

HT

HO

1.0

12

Soft confluent drusen; middle subfield

5(B), 6(V3), 6(V6), 6(V9), 5(V12)

25, F, 81

HT

HT

0.8

6

Soft drusen; middle subfield

4(B), 6(V3), 6(V6)

26, F, 52

HT

HT

0.6

12

Soft drusen; middle subfield

6(B), 6(V3), 6(V6), 6(V9), 6(V12)

27, F, 73

HO

WT

1.0

12

Soft drusen and hyperpigm.; middle subfield

3(B), 5(V3), 5(V6), 5(V9), 5(V12)

28, F, 68

HO

WT

0.6

12

Soft confluent drusen; central subfield

6(B), 5(V3), 5(V6), 5(V9), 5(V12)

29, F,51

WT

WT

0.5

12

Soft drusen; middle subfield

5(B), 6(V3), 6(V6), 6(V9), 6(V12)

30, F, 84

HT

HT

0.5

6

Soft drusen and hyperpigm.; central subfield

3(B), 3(V3), 4(V6)

31, F, 63

WT

WT

0.7

12

Soft drusen; central and middle subfield

5(B), 6(V3), 6(V6), 6(V9), 5(V12)

32, M,85

WT

WT

0.8

12

Soft drusen; central and middle subfield

5(B), 5(V3), 5(V6), 5(V9), 5(V12)

33, F,74

HT

WT

0.9

6

Soft drusen and hyperpigm.; middle subfield

5(B), 6(V3), 6(V6)

  1. Follow-up duration (months). *Macular appearance with reference to drusen type, confluence, and location; RPE abnormality type and main location. §Number of FERG responses that were above noise level (i.e., S/N ratio ≥ 3) at the different modulation depths of the recording protocol; (6) = S/N ratio ≥ 3 at all modulation depths, (5) = S/N ratio < 3 at the two lowest modulation depths, (4) = S/N ratio < 3 at the three lowest modulation depths, etc., B: baseline V3, V6, V9, V12: months of supplementation.